AIR COMMERCIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL SINGLE- TENANT LEASE — NET (DO NOT USE THIS FORM FOR MULTI-TENANT BUILDINGS)Office Lease • May 24th, 2019 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • California
S09-398 : CKC EXCLUSIVE (EQUITY) AGREEMENT CONFIDENTIALExclusive (Equity) Agreement • May 24th, 2019 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • California
This Exclusive (Equity) Agreement (this “Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Eidos Therapeutics, Inc. (“Eidos”), a corporation having a principal place of business at 12354 Skyline Boulevard, Woodside, CA 94062, is effective on the 10th day of April, 2016 (“Effective Date”).
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 24th, 2019 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • California
THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of May 17, 2019 is entered into by and among BRIDGEBIO PHARMA LLC, a Delaware limited liability company (“Parent”), BRIDGEBIO SERVICES INC., a Delaware corporation (“Services Company”), SUB20, INC., a Delaware corporation (“Sub20”, and together with Parent, Services Company and each other Person party thereto from time to time as borrower, from time to time, collectively, “Borrowers”, and each, a “Borrower”), and the several banks and other financial institutions or entities party thereto as Lender, constituting the Required Lenders and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for Lender (in such capacity, “Agent”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 24th, 2019 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • California
THIS LOAN AND SECURITY AGREEMENT is made and dated as of June 19, 2018 and is entered into by and among BRIDGEBIO PHARMA LLC, a Delaware limited liability company (“Parent”), BRIDGEBIO SERVICES INC., a Delaware corporation (“Services Company”), and each of their Qualified Subsidiaries from time to time party hereto (Parent, Services Company and each such Qualified Subsidiary, individually, each, a “Borrower”, and collectively, “Borrowers”), the several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, “Lender”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for Lender (in such capacity, “Agent”).
OPTION AGREEMENT by and among LEO PHARMA A/S LEO SPINY MERGER SUB, INC. AND PELLEPHARM, INC. Dated as of November 19, 2018Agreement of Merger • May 24th, 2019 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT OF MERGER (this “Agreement”), dated as of November 19, 2018, is entered into by and among LEO Pharma A/S, a company organized under the laws of the Kingdom of Denmark (“Parent”), LEO Spiny Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), PellePharm, Inc., a Delaware corporation (the “Company”), and Fortis Advisors LLC, a Delaware limited liability company, as the Equityholder Representative (together with Parent, Merger Sub and the Company, the “Parties”).
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 24th, 2019 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • California
THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of December 28, 2018 is entered into by and among BRIDGEBIO PHARMA LLC, a Delaware limited liability company (“Parent”), BRIDGEBIO SERVICES INC., a Delaware corporation (“Services Company”), SUB20, INC., a Delaware corporation (“Sub20”, and together with Parent, Services Company and each other Person party hereto from time to time as borrower, from time to time, collectively, “Borrowers”, and each, a “Borrower”), and the several banks and other financial institutions or entities party thereto as Lender, constituting the Required Lenders and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for Lender (in such capacity, “Agent”).
ASSET PURCHASE AGREEMENT between ALEXION PHARMA HOLDING UNLIMITED COMPANY, ORIGIN BIOSCIENCES, INC., and BRIDGEBIO PHARMA, LLC (SOLELY FOR THE PURPOSES OF SECTION 6.14) DATED AS OF June 7, 2018Asset Purchase Agreement • May 24th, 2019 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • Delaware
This Asset Purchase Agreement, dated as of June 7, 2018 (the “Effective Date”), by and between Alexion Pharma Holding Unlimited Company, an unlimited liability company incorporated under the laws of Ireland (“Seller”), Origin Biosciences, Inc., a Delaware corporation (“Purchaser”) and BridgeBio Pharma, LLC, a Delaware limited liability company (“BridgeBio”) (solely for the purposes of Section 6.14).
